cure for cancer is within reach, even optimistically predicting that it will be found within a year.
But at least one expert in the U.S. has questioned the potential cure’s legitimacy and said it’s more likely just another claim on a list of “irresponsible and ultimately cruel false promises” for cancer patients.
“More likely, this claim is yet another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”
“We believe we will offer in a year’s time a complete cure for cancer,” Dan Aridor, of AEBi, said.
The company’s CEO, Dr. Ilan Morad, said MuTaTo also works to target cancer stem cells, eliminating the chances of recurrence, with Aridor claiming that it will be effective from “Day 1” and cause “no or minimal side effects at a much lower cost than most other treatments.”
“Our solution will be both generic and personal,” Aridor said.
But Dr. Ben Neel, director of Perlmutter Cancer Center at NYU Langone Health, is skeptical, telling Fox News via email: “Of course, curing cancer is the goal of everyone who comes to work every day at a cancer center — and if this company does, in fact, cure cancer, they will have my congratulations and thanks. But cancer is multiple diseases, and it is highly unlikely that this company has found a ‘cure’ for cancer, anymore than there is a single cure for infections.”
The treatment has not been tested in humans yet, although Aridor said it has shown success in mice and is nearing the clinical trial stage.
Said Neel, “More likely, this claim is yet another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”
“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd., which is developing the new treatment.
Most cancer drugs attack a specific target on, or in the cancer cell, said AEBi CEO Dr. Ilan Morad. They fail because that target mutates, changing to divide and spread and avoid attack. But Morad claims MuTaTo “will not be affected by mutations” because the treatment attacks at least three targets at a time.
Morad said MuTaTo is also strong enough to both destroy stem cells and penetrate where other drugs cannot reach. He says it will dramatically decrease side effects because it does not target non-cancerous cells as current cancer drugs do.
The treatment will eventually be personalized and a specific cocktail of the drugs will be given to patients based on their type of cancer, said Dr. Morad.
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” said Aridor. “Our solution will be both generic and personal.”
AEBi says it has successfully tested the drug in mice. The company now plans to move forward with clinical trials and make the treatment available within a few years.